Methotrexate treatment suppresses local cytokine and chemokine production in rat adjuvant arthritis

Drugs under Experimental and Clinical Research

Volumn 31, Issue 1, 2005, Pages 7-11

  Barsig, J ^a   Yam, G ^a   Lehner, M D ^a   Beume, R ^a  

^a ALTANA PHARMA AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE; CYTOKINE; METHOTREXATE;

ADJUVANT ARTHRITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DOSE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; MALE; NONHUMAN; PAW EDEMA; RAT; RHEUMATOID ARTHRITIS; SCORING SYSTEM; STANDARD;

ANIMALS; ANTIRHEUMATIC AGENTS; ARTHRITIS, EXPERIMENTAL; CHEMOKINES; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, DRUG; MALE; METHOTREXATE; RATS; RATS, INBRED LEW;

EID: 16244404236     PISSN: 03786501     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Kremer J.M. Rational use of new and existing disease-modifying agents in rheumatoid arthritis. Ann. Intern. Med., 134, 695, 2001.
2. Genestier L., Paillot R., Quemeneur L., Izeradjene K., Revillard J.P. Mechanisms of action of methotrexate. Immunopharmacology, 47, 247, 2000.
3. Chan E.S., Cronstein B.N. Molecular action of methotrexate in inflammatory diseases. Arthritis Res., 4, 266, 2002.
4. Bendele A., McComb J., Gould T., et al. Animal models of arthritis: Relevance to human disease. Toxicol. Pathol., 27, 134, 1999.
5. Magari K., Miyata S., Nishigaki F., Ohkubo Y., Mutoh S., Goto T. Differential effects of FK506 and methotrexate on inflammatory cytokine levels in rat adjuvant-induced arthritis. J. Rheumatol., 30, 2193, 2003.
6. Olsen N.J., Stein C.M. New drugs for rheumatoid arthritis. N. Engl. J. Med., 350, 2167, 2004.
7. Greenwald R.A. Animal models for evaluation of arthritis drugs. Methods Find. Exp. Clin. Pharmacol., 13, 75, 1991.
8. Nishimoto N., Kishimoto T. Inhibition of IL-6 for the treatment of inflammatory diseases. Curr. Opin. Pharmacol., 4, 386, 2004.
9. Kunkel S.L., Lukacs N., Kasama T., Strieter R.M. The role of chemokines in inflammatory joint disease. J. Leukoc. Biol., 59, 6, 1996.
10. Volin M.V., Shah M.R., Tokuhira M., Haines G.K., Woods J.M., Koch A.E. RANTES expression and contribution to monocyte chemotaxis in arthritis. Clin. Immunol. Immunopathol., 89, 44, 1998.
11. Koenig A., Krenn V., Toksoy A., Gerhard N., Gillitzer R. Mig, GROalpha and RANTES messenger RNA expression in lining layer, infiltrates and different leucocyte populations of synovial tissue from patients with rheumatoid arthritis, psoriatic arthritis and osteoarthritis. Virchows. Arch., 436, 449, 2000.
12. Rathanaswami P., Hachicha M., Sadick M., Schall T.J., McColl S.R. Expression of the cytokine RANTES in human rheumatoid synovial fibroblasts. Differential regulation of RANTES and interleukin-8 genes by inflammatory cytokines. J. Biol. Chem., 268, 5834, 1993.
13. Smith-Oliver T., Noel L.S., Stimpson S.S., Yarnall D., Connolly K.M. Elevated levels of TNF in the joints of adjuvant arthritic rats. Cytokine, 5, 298, 1993.
14. Szekanecz Z., Halloran M.M., Volin M.V., et al. Temporal expression of inflammatory cytokines and chemokines in rat adjuvant-induced arthritis. Arthritis Rheum., 43(6), 1266, 2000.
15. Barnes D.A., Tse J., Kaufhold M., et al. Polyclonal antibody directed against human RANTES ameliorates disease in the Lewis rat adjuvant-induced arthritis model. J. Clin. Invest., 101, 2910, 1998.
16. Bendele A.M., Chlipala E.S., Scherrer J., et al. Combination benefit of treatment with the cytokine inhibitors interleukin-1 receptor antagonist and PECylated soluble tumor necrosis factor receptor type I in animal models of rheumatoid arthritis. Arthritis Rheum., 43, 2648, 2000.
17. Feige U., Hu Y.L., Gasser J., Campagnuolo G., Munyakazi L., Bolon B. Anti-interleukin-1 and anti-tumor necrosis factor-alpha synergistically inhibit adjuvant arthritis in Lewis rats. Cell Mol. Life Sci. 57, 1457, 2000.
18. Guglielmotti A., Onofrio E., Coletta I., Aquilini L., Milanese C., Pinza M. Amelioration of rat adjuvant arthritis by therapeutic treatment with bindarit, an inhibitor of MCP-1 and TNF-alpha production. Inflamm. Res., 51, 252, 2002.